Turnover: 50.5 billion USD (2022)

Country: Switzerland

  • Novartis is a Swiss pharmaceutical group.
  • The company focuses on pharmaceuticals, generics and eye care.

News

Novartis raises its outlook and prepares to spin off Sandoz 18/07/2023

Spin-off and IPO of Sandoz generics division planned for early fourth quarter

Pharmaceuticals Novartis acquires American Chinook Therapeutics for $3.5 billion 13/06/2023

  • Total consideration for Novartis acquisition of Chinook Therapeutics: up to $3.5 billion (€3.2 billion).
  • Chinook Therapeutics is developing two drugs in advanced clinical trials for immunoglobulin A (IgA) nephropathy, a rare kidney disease.
  • Up to three out of ten patients with this disease progress to kidney failure and require dialysis within ten years.

Medicines: 400 jobs threatened at Novartis France 21/01/2023

  • Novartis France employs 2,900 people
  • The French subsidiary's two plants, in Huningue (Alsace) and Les Ulis (Essonne), are not affected

Financial Data

DUNS: 410349070

Legal Name: NOVARTIS PHARMA SAS

Address: 8 RUE HENRI STE CLAIRE DEVILLE 8-10, 92500 RUEIL-MALMAISON

Number of employees: Entre 2 000 et 4 999 salariés (2020)

Capital: 43 380 000 EUR


Financial Data:

Year 2021 2020 2019 2018 2017 2016 2015
Turnover 2 290 391 954 2 161 437 967 2 212 759 512 2 226 228 320 2 077 156 401 1 963 124 586 1 824 897 398
Gross margin (€) 1 028 981 842 925 650 110 925 877 351 954 029 949 822 900 808 732 167 540 694 455 974
EBITDA (€) 148 156 867 146 507 201 144 118 876 126 432 797 94 172 545 100 426 140 84 398 588
Operating profit (€) 124 659 232 116 879 584 126 127 127 108 144 030 77 662 725 86 960 513 66 440 955
Net profit (€) 46 999 320 -19 614 721 84 713 094 12 415 870 28 773 236 55 263 934 -2 212 262
Turnover growth rate (%) 6 -2,3 -0,6 7,2 5,8 7,6 -
Ebitda margin rate (%) 6,5 6,8 6,5 5,7 4,5 5,1 4,6
Operating margin rate (%) 5,4 5,4 5,7 4,9 3,7 4,4 3,6
Working Capital (turnover days) -5,3 -20,1 -5,5 -10,2 -5,7 4,6 3,3
Working Capital requirements (turnover days) 43,9 43,3 37,6 26,1 48,1 47,4 45,5
Net margin (%) 2,1 -0,9 3,8 0,6 1,4 2,8 -0,1
Added value / Turnover (%) 36,4 33,8 31,2 32,3 28,3 25,7 25,7
Wages and social charges (€) 258 213 112 256 706 402 259 265 595 260 454 408 255 273 928 233 350 345 232 949 685
Salaries / Turnover (%) 11,3 11,9 11,7 11,7 12,3 11,9 12,8

Company Managers:

Position First Name Last Name Age Linkedin
Président Thibaut MICHEL 45
Directeur général Vincent HERZOG 42

Studies mentioning this company

The market for plant protection products - France

Other companies mentioned:

The pharmacy market - France

Other companies mentioned:

The pharmacy market - Spain

Other companies mentioned:

  • Sanofi Aventis
  • Novartis
  • Hygie 31
  • Johnson & Johnson
  • Pfizer
  • Roche Groupe
  • Cofares S.c. Farmaceutica Española
  • Grupo Bidafarma S.c. Andaluza De Segundo Grado
  • Alliance Healthcare España Sociedad Anonima
  • Hermandad Farmaceutica Del Mediterraneo S.c.l.
  • Grupo Unnefar S.c.
  • Janssen Cilag Sa
  • Merck Sharp & Dohme De España Sau
  • Almirall
The hydro-alcoholic gels market - France

Other companies mentioned:

The market of pharmacies - Germany

Other companies mentioned: